These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 2069792)

  • 1. The Helsinki Heart Study: central findings and clinical implications.
    Huttunen JK; Manninen V; Mänttäri M; Koskinen P; Romo M; Tenkanen L; Heinonen OP; Frick MH
    Ann Med; 1991 Apr; 23(2):155-9. PubMed ID: 2069792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relation between baseline lipid and lipoprotein values and the incidence of coronary heart disease in the Helsinki Heart Study.
    Manninen V; Huttunen JK; Heinonen OP; Tenkanen L; Frick MH
    Am J Cardiol; 1989 May; 63(16):42H-47H. PubMed ID: 2650524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Helsinki Heart Study. New perspectives in the prevention of coronary heart disease.
    Huttunen JK; Frick MH; Heinonen OP; Heinsalmi P; Manninen V; Mänttäri M; Romo M
    Drugs; 1988; 36 Suppl 3():32-6. PubMed ID: 3076118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rationale and design of the Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial (HIT) for secondary prevention of coronary artery disease in men with low high-density lipoprotein cholesterol and desirable low-density lipoprotein cholesterol.
    Rubins HB; Robins SJ; Iwane MK; Boden WE; Elam MB; Fye CL; Gordon DJ; Schaefer EJ; Schectman G; Wittes JT
    Am J Cardiol; 1993 Jan; 71(1):45-52. PubMed ID: 8420235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipoproteins and coronary heart disease in the Helsinki Heart Study.
    Mänttäri M; Huttunen JK; Koskinen P; Manninen V; Tenkanen L; Heinonen OP; Frick MH
    Eur Heart J; 1990 Dec; 11 Suppl H():26-31. PubMed ID: 2073911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of regular and extended-release gemfibrozil on plasma lipoproteins and apolipoproteins in hypercholesterolemic patients with decreased HDL cholesterol levels.
    Schaefer EJ; Lamon-Fava S; Cole T; Sprecher DL; Cilla DD; Balagtas CC; Rowan JP; Black DM
    Atherosclerosis; 1996 Nov; 127(1):113-22. PubMed ID: 9006811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment.
    Manninen V; Tenkanen L; Koskinen P; Huttunen JK; Mänttäri M; Heinonen OP; Frick MH
    Circulation; 1992 Jan; 85(1):37-45. PubMed ID: 1728471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease.
    Frick MH; Elo O; Haapa K; Heinonen OP; Heinsalmi P; Helo P; Huttunen JK; Kaitaniemi P; Koskinen P; Manninen V
    N Engl J Med; 1987 Nov; 317(20):1237-45. PubMed ID: 3313041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes of lipoprotein profile in familial dysbetalipoproteinemia with gemfibrozil.
    Zhao SP; Smelt AH; Leuven JA; Vroom TF; van der Laarse A; van 't Hooft FM
    Am J Med; 1994 Jan; 96(1):49-56. PubMed ID: 8304363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analyzing of high-density lipoprotein subfractions and low-density lipoprotein subfractions in human serum with anion-exchange chromatography.
    Hirowatari Y; Tsunoda Y; Ogura Y; Homma Y
    Atherosclerosis; 2009 Jun; 204(2):e52-7. PubMed ID: 19091316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of simvastatin, bezafibrate and gemfibrozil on the quantity and composition of plasma lipoproteins.
    Nakandakare E; Garcia RC; Rocha JC; Sperotto G; Oliveira HC; Quintão EC
    Atherosclerosis; 1990 Dec; 85(2-3):211-7. PubMed ID: 2102085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial.
    Robins SJ; Collins D; Wittes JT; Papademetriou V; Deedwania PC; Schaefer EJ; McNamara JR; Kashyap ML; Hershman JM; Wexler LF; Rubins HB;
    JAMA; 2001 Mar; 285(12):1585-91. PubMed ID: 11268266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive value for coronary heart disease of baseline high-density and low-density lipoprotein cholesterol among Fredrickson type IIa subjects in the Helsinki Heart Study.
    Manninen V; Koskinen P; Manttari M; Huttunen JK; Canter D; Frick HM
    Am J Cardiol; 1990 Sep; 66(6):24A-27A. PubMed ID: 2392990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gemfibrozil therapy in primary type II hyperlipoproteinemia: effects on lipids, lipoproteins and apolipoproteins.
    Lupien PJ; Brun D; Gagné C; Moorjani S; Bielman P; Julien P
    Can J Cardiol; 1991; 7(1):27-33. PubMed ID: 2025787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical study of the month. Usefulness of increasing HDL cholesterol in secondary prevention of coronary heart disease: results of the VA-HIT study].
    Scheen AJ
    Rev Med Liege; 1999 Sep; 54(9):773-5. PubMed ID: 10589275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gemfibrozil prevents major coronary events by increasing HDL-cholesterol and more.
    Doggrell SA
    Expert Opin Pharmacother; 2001 Jul; 2(7):1187-9. PubMed ID: 11583069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cholesterol Levels of Six Fractionated Serum Lipoproteins and its Relevance to Coronary Heart Disease Risk Scores.
    Manita D; Yoshida H; Hirowatari Y
    J Atheroscler Thromb; 2017 Sep; 24(9):928-939. PubMed ID: 28025448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of honey intake on serum cholesterol, triglycerides and lipoprotein levels in albino rats and potential benefits on risks of coronary heart disease.
    Alagwu EA; Okwara JE; Nneli RO; Osim EE
    Niger J Physiol Sci; 2011 Dec; 26(2):161-5. PubMed ID: 22547185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rationale for use of non-high-density lipoprotein cholesterol rather than low-density lipoprotein cholesterol as a tool for lipoprotein cholesterol screening and assessment of risk and therapy.
    Frost PH; Havel RJ
    Am J Cardiol; 1998 Feb; 81(4A):26B-31B. PubMed ID: 9526810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipoprotein profiling by high performance gel chromatography.
    Tallis GA; Shephard MD; Whiting MJ
    Clin Chim Acta; 1994 Aug; 228(2):171-9. PubMed ID: 7988033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.